IP Library Granted Patent US 10,941,097
Granted Patent B2
US 10,941,097 · App. 16/604,244 · Granted Mar 9, 2021

Methods for manufacturing phenoxyethanol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,941,097
App. No.
16/604,244
Granted
Mar 9, 2021
Kind
B2
Abstract

Methods for manufacturing phenoxyethanol from a reaction of a phenolate with a monohalohydrin. The phenolate is reacted with the monohalohydrin at a reaction temperature that is less than or equal to a boiling point of a reaction mixture to produce products that include the phenoxyethanol.

Claims (26)

1. A method for manufacturing phenoxyethanol, the method comprising:

reacting phenolate with a monohalohydrin at a reaction temperature that is less than or equal to a boiling point of a reaction mixture, wherein a catalyst is not present, to produce products that include the phenoxyethanol.

2. The method of claim 1 , further comprising:

cooling the reaction mixture;

extracting the products from the cooled reaction mixture by addition of an organic solvent immiscible in water to form an organic phase;

washing the organic phase with an alkaline aqueous solution; and

subsequent to washing the organic phase, fractionally distilling the phenoxyethanol from the washed organic phase.

3. The method of claim 2 , wherein the organic solvent comprises methylene chloride.

4. The method of claim 2 , wherein the alkaline aqueous solution comprises a sodium hydroxide solution.

5. The method of claim 2 , wherein fractionally distilling the phenoxyethanol from the washed organic phase further comprises:

heating to a distilling temperature of about 95° C. to about 120° C.

6. The method of claim 5 , wherein fractionally distilling the phenoxyethanol from the washed organic phase further comprises:

heating while under decreased pressure.

7. The method of claim 5 , wherein fractionally distilling the phenoxyethanol from the washed organic phase further comprises:

heating to the distilling temperature while at atmospheric pressure.

8. The method of claim 1 , wherein the reaction mixture of the phenolate and the monohalohydrin is aqueous.

9. The method of claim 1 , wherein the phenolate is an alkali metal phenolate hydrate.

10. The method of claim 9 , wherein the phenolate is a sodium phenolate trihydrate.

11. The method of claim 1 , wherein the monohalohydrin is a 2-haloethanol.

12. The method of claim 11 , wherein the 2-haloethanol comprises a halogen selected from the group consisting of chloro-, bromo-, iodo-, and fluoro-.

13. The method of claim 1 , wherein the reaction temperature is about 65° C. to about 75° C.

14. The method of claim 1 , wherein reacting the phenolate with the monohalohydrin comprises:

adding the monohalohydrin to the phenolate dropwise for a period of time.

15. The method of claim 1 , wherein the phenoxyethanol includes less than or equal to 0.10% w/w of phenol.

16. The method of claim 15 , wherein the phenoxyethanol includes less than or equal to 0.10% w/w of each of one or more unspecified impurities.

17. The method of claim 16 , wherein one of the one or more unspecified impurities is 2-(2-phenoxyethoxy)ethanol.

Assignments (12)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2021
From: DABROWSKA-MAS, ELZBIETA; RAS, WOJCIECH; ATAMAN, BARTLOMIEJ; SMOLAK, KAZIMIERZ; PSZENICZNY, ADAM
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 055043/0825 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 051797/0416 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 4, 2020
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; BAUSCH HEALTH US, LLC; SANTARUS, INC.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT FOR THE NOTEHOLDER SECURED PARTIES
Reel/Frame 051797/0491 →